S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

$491.29
-6.50 (-1.31%)
(As of 04/15/2024 ET)
Today's Range
$489.81
$506.57
50-Day Range
$491.29
$576.87
52-Week Range
$372.50
$583.39
Volume
495,344 shs
Average Volume
424,484 shs
Market Capitalization
$40.80 billion
P/E Ratio
48.79
Dividend Yield
N/A
Price Target
$591.50

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
20.4% Upside
$591.50 Price Target
Short Interest
Healthy
2.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
1.04mentions of IDEXX Laboratories in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$24.87 M Sold Last Quarter
Proj. Earnings Growth
14.53%
From $11.15 to $12.77 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.64 out of 5 stars

Medical Sector

58th out of 929 stocks

Diagnostic Substances Industry

2nd out of 12 stocks

IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
IDXX Oct 2024 780.000 call
IDXX Apr 2024 280.000 put
IDXX Jun 2024 640.000 call
IDXX Feb 2024 550.000 call
IDEXX Laboratories Inc Insider Sells Shares
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
4/15/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
11,000
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$591.50
High Stock Price Target
$655.00
Low Stock Price Target
$460.00
Potential Upside/Downside
+20.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$845.04 million
Pretax Margin
28.99%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$11.41 per share
Book Value
$17.88 per share

Miscellaneous

Free Float
81,243,000
Market Cap
$40.80 billion
Optionable
Optionable
Beta
1.26

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Recent increase in institutional holdings by key investors indicates confidence in the company's future growth prospects.
  • IDEXX Laboratories operates in multiple segments including Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy, diversifying its revenue streams.
  • The company offers a wide range of diagnostic products and services for veterinary, livestock, and water testing markets, catering to diverse customer needs.
  • Strong market presence in various regions globally, providing opportunities for continued expansion and revenue growth.
  • Current stock price is relatively stable and has shown positive momentum in recent periods, presenting a potential investment opportunity.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Market competition in the diagnostic substances industry may impact IDEXX Laboratories' market share and pricing power.
  • Regulatory changes or challenges in different regions could affect the company's operations and profitability.
  • Economic downturns or global health crises may impact demand for veterinary and diagnostic products, affecting the company's financial performance.
  • Dependency on key markets like companion animal veterinary and livestock sectors for a significant portion of revenue, exposing the company to sector-specific risks.
  • Fluctuations in raw material costs or supply chain disruptions could impact IDEXX Laboratories' production costs and margins.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

9 brokers have issued 1 year price targets for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $655.00. On average, they predict the company's share price to reach $591.50 in the next year. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 at the beginning of the year. Since then, IDXX stock has decreased by 11.5% and is now trading at $491.29.
View the best growth stocks for 2024 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IDXX earnings forecast
.

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Monday, February, 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. The firm earned $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a trailing twelve-month return on equity of 71.66% and a net margin of 23.08%. IDEXX Laboratories's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 earnings per share.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share guidance of 10.840-11.330 for the period, compared to the consensus estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Westwind Capital (0.05%), Bourne Lent Asset Management Inc. (0.05%), Woodstock Corp (0.03%), Bath Savings Trust Co (0.03%), Czech National Bank (0.02%) and Gateway Investment Advisers LLC (0.01%). Insiders that own company stock include Brian P Mckeon, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners